Routine renin-angiotensin system blockade in renal transplantation?

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

There is ample evidence to support the recommendation of renin-angiotensin system blockade therapy as the standard of care for strategies aimed at preserving renal function in chronic renal disease. Nevertheless, despite the well established antihypertensive effects of these drugs, the use of renin-angiotensin system blockers in renal transplantation has been quite limited so far, nephrologists being afraid of the possibility of inducing renal insufficiency in patients with a single kidney transplant. However, current knowledge of the ability of these agents to control blood pressure and urinary protein excretion, as well as post-transplant erythrocytosis, effectively in kidney transplant recipients suggests that it is now time to apply renin-angiotensin system blockers to the field of renal transplantation.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalCurrent Opinion in Nephrology and Hypertension
Volume11
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Renin-Angiotensin System
Kidney Transplantation
Kidney
Transplants
Polycythemia
Standard of Care
Chronic Renal Insufficiency
Antihypertensive Agents
Renal Insufficiency
Blood Pressure
Proteins
Therapeutics

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

@article{0992045ef4524055a4e1d981528ed076,
title = "Routine renin-angiotensin system blockade in renal transplantation?",
abstract = "There is ample evidence to support the recommendation of renin-angiotensin system blockade therapy as the standard of care for strategies aimed at preserving renal function in chronic renal disease. Nevertheless, despite the well established antihypertensive effects of these drugs, the use of renin-angiotensin system blockers in renal transplantation has been quite limited so far, nephrologists being afraid of the possibility of inducing renal insufficiency in patients with a single kidney transplant. However, current knowledge of the ability of these agents to control blood pressure and urinary protein excretion, as well as post-transplant erythrocytosis, effectively in kidney transplant recipients suggests that it is now time to apply renin-angiotensin system blockers to the field of renal transplantation.",
author = "Guiseppe Remuzzi and Norberto Perico",
year = "2002",
doi = "10.1097/00041552-200201000-00001",
language = "English",
volume = "11",
pages = "1--10",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Routine renin-angiotensin system blockade in renal transplantation?

AU - Remuzzi, Guiseppe

AU - Perico, Norberto

PY - 2002

Y1 - 2002

N2 - There is ample evidence to support the recommendation of renin-angiotensin system blockade therapy as the standard of care for strategies aimed at preserving renal function in chronic renal disease. Nevertheless, despite the well established antihypertensive effects of these drugs, the use of renin-angiotensin system blockers in renal transplantation has been quite limited so far, nephrologists being afraid of the possibility of inducing renal insufficiency in patients with a single kidney transplant. However, current knowledge of the ability of these agents to control blood pressure and urinary protein excretion, as well as post-transplant erythrocytosis, effectively in kidney transplant recipients suggests that it is now time to apply renin-angiotensin system blockers to the field of renal transplantation.

AB - There is ample evidence to support the recommendation of renin-angiotensin system blockade therapy as the standard of care for strategies aimed at preserving renal function in chronic renal disease. Nevertheless, despite the well established antihypertensive effects of these drugs, the use of renin-angiotensin system blockers in renal transplantation has been quite limited so far, nephrologists being afraid of the possibility of inducing renal insufficiency in patients with a single kidney transplant. However, current knowledge of the ability of these agents to control blood pressure and urinary protein excretion, as well as post-transplant erythrocytosis, effectively in kidney transplant recipients suggests that it is now time to apply renin-angiotensin system blockers to the field of renal transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0036140943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036140943&partnerID=8YFLogxK

U2 - 10.1097/00041552-200201000-00001

DO - 10.1097/00041552-200201000-00001

M3 - Article

VL - 11

SP - 1

EP - 10

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 1

ER -